Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells

Yuki Nishida, Hideaki Mizuno, Edward Ayoub, Eiji Sugihara, Lauren B. Ostermann, Shayaun Khazaei, Darah Scruggs, Po Yee Mak, Baozhen Ke, Bing Z. Carter, Abhishek Maiti, Liandong Ma, Michael Andreeff

Blood (2024) 144 (Supplement 1): 2755.

https://doi.org/10.1182/blood-2024-207812

Published: 2024

Journal Articles

Reactivation of p53 in TP53 -Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Xiaogang Wu, Steffen Boettcher, Lauren B. Ostermann, Andrea Bedoy, Georgina Gener-Ricos, Jayastu Senapati, Courtney D. DiNardo, Anna Puzio-Kuter, Arnold Levine, Michael Andreeff

Blood (2024) 144 (Supplement 1): 4155.

https://doi.org/10.1182/blood-2024-208403

Published: 2024

Journal Articles

Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC

Blood (2023) 142 (Supplement 1): 583.

https://doi.org/10.1182/blood-2023-174938

Published: 2023

Journal Articles

Novel Hypomethylating Agent Ntx-301 Exhibits Anti-Leukemia Activity in Venetoclax-Resistant and TP53-Mutant AML

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Andrea Bedoy, Steffen Boettcher, Lauren B. Ostermann, Elizabeth J. Shpall, Michael Andreeff

Blood (2023) 142 (Supplement 1): 4158.

https://doi.org/10.1182/blood-2023-180051

Published: 2023

Journal Articles

Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-202) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models

Muharrem Muftuoglu, Mahesh Basyal, Li Li, Jiangxing Lv, Lauren B. Ostermann, Ran Zhao, Baozhen Ke, Hiroki Akiyama, Po Yee Mak, Bing Z. Carter, Han Deng, Yongshuai Li, Brian S. Garrison, Kanya L. Rajangam, Michael Andreeff

Blood (2023) 142 (Supplement 1): 4831.

https://doi.org/10.1182/blood-2023-191127

Published: 2023

Journal Articles

Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2

Bing Z. Carter, Po Yee Mak, Baozhen Ke, Yuki Nishida, Steffen Boettcher, Andrea Bedoy, Lauren B. Ostermann, Courtney D. DiNardo, Anna Puzio-Kuter, Arnold Levine, Michael Andreeff

Blood (2023) 142 (Supplement 1): 2261.

https://doi.org/10.1182/blood-2023-181186

Published: 2023

Journal Articles

Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia

Hiroki Akiyama, Matthew Tcheng, Priyanka Sharma, Ran Zhao, Lauren B. Ostermann, Samar Yazdani, Arman Moayed, Zdzislaw Szulc, Natalia Oleinik, Po Yee Mak, Vivian Ruvolo, Bing Z. Carter, Besim Ogretmen, Gautam Borthakur, Aaron D. Schimmer, Michael Andreeff, Jo Ishizawa

Blood (2023) 142 (Supplement 1): 2804.

https://doi.org/10.1182/blood-2023-181410

Published: 2023

Journal Articles

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

Blood (2023) 142 (12): 1056–1070.

https://doi.org/10.1182/blood.2022019047

Published: 2023

Includes: Supplemental data

Journal Articles

Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3 -ITD/-TKD Mutant AML in a PDX Model

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Duncan Mak, Boazhen Ke, Peter Ordentlich, Gerard M. McGeehan, Michael Andreeff

Blood (2022) 140 (Supplement 1): 3063–3064.

https://doi.org/10.1182/blood-2022-158570

Published: 2022

Journal Articles

Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia

Hiroki Akiyama, Ran Zhao, Yuki Nishida, Natalia Baran, Ziyi Li, Lauren B Ostermann, Po Yee Mak, Edward Ayoub, Sujan Piya, Bing Z Carter, Michael Andreeff, Jo Ishizawa

Blood (2022) 140 (Supplement 1): 8785–8786.

https://doi.org/10.1182/blood-2022-162354

Published: 2022

Journal Articles

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Yuki Nishida, Naveen Pemmaraju, Steffen Boettcher, Elizabeth J Shpall, Gabriela Chiosis, Georgios Karras, Barbara Wallner, Robert A Morgan, Michael Andreeff

Blood (2022) 140 (Supplement 1): 5930–5931.

https://doi.org/10.1182/blood-2022-158547

Published: 2022

Journal Articles

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53 -Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Yuki Nishida, Darah A Scruggs, Edward Ayoub, Tallie Patsilevas, Vivian Ruvolo, Po Yee Mak, Bing Z Carter, Steffen Boettcher, Abhishek Maiti, Qianxiang Zhou, Zhaohui Yang, Honghua Yan, Liandong Ma, Michael Andreeff

Blood (2022) 140 (Supplement 1): 483–484.

https://doi.org/10.1182/blood-2022-164968

Published: 2022

Journal Articles

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Yuki Nishida, Jo Ishizawa, Edward Ayoub, Tallie Patsilevas, Lauren Ostermann, Rafael Heinz Montoya, Muharrem Muftuoglu, Vivian Ruvolo, Po Yee Mak, Wenjing Tao, Bing Z Carter, Kensuke Kojima, Naval Daver, Arnaud Lesegretain, Takahiko Seki, Sharon Shacham, Marina Konopleva, Michael Andreeff

Blood (2021) 138 (Supplement 1): 505.

https://doi.org/10.1182/blood-2021-149260

Published: 2021

Journal Articles

Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics

Bing Z Carter, Po Yee Mak, Wenjing Tao, Lauren B Ostermann, Steffen Boettcher, Yuki Nishida, Edward Ayoub, Vivian Ruvolo, Elias J. Jabbour, Paul Hughes, PK Morrow, Michael Andreeff

Blood (2021) 138 (Supplement 1): 2239.

https://doi.org/10.1182/blood-2021-148014

Published: 2021

Journal Articles

Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy

Kyung Hee Chang, Tomasz Zal, Mahesh Basyal, Lauren Ostermann, Muharrem Muftuoglu, Po Yee Mak, Yannan Jia, Wenjing Tao, Malgorzata Anna Zal, William E. Fogler, John L. Magnani, Weiguo Zhang, Bing Z Carter, Michael Andreeff

Blood (2021) 138 (Supplement 1): 3348.

https://doi.org/10.1182/blood-2021-153661

Published: 2021

Journal Articles

Co-Targeting Intrinsic and Extrinsic Apoptosis to Maximize Cell Death Induction in Venetoclax-Resistant AML Cells

Bing Z Carter, Wenjing Tao, Lauren B Ostermann, Hong Mu-Mosley, Po Yee Mak, Steffen Boettcher, Yuki Nishida, Ran Tao, Eric Lang, Yifan Zhai, Dajun Yang, Michael Andreeff

Blood (2021) 138 (Supplement 1): 3332.

https://doi.org/10.1182/blood-2021-148127

Published: 2021

Journal Articles

Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML

Bing Z. Carter, Wenjing Tao, Po Yee Mak, Lauren B. Ostermann, Duncan Mak, Gerard McGeehan, Peter Ordentlich, Michael Andreeff

Blood (2021) 138 (17): 1637–1641.

https://doi.org/10.1182/blood.2021011917

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

Bing Z Carter, PhD, Po Yee Mak, Vivian Ruvolo, MS, Wenjing Tao, Paul Hughes, Xiaoyue Chen, PK Morrow, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-141399

Published: 2020

Journal Articles

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

Kotoko Yamatani, MD, Tomohiko Ai, MDPhD, Kaori Saito, Haeun Yang, Vivian Ruvolo, MS, Po Yee Mak, Sonoko Kinjo, PhD, Kazuho Ikeo, PhD, Hironori Harada, MD PhD, Kazuhiro Katayama, PhD, Takashi Miida, MD PhD, Marina Konopleva, MD PhD, Weiguo Zhang, MD PhD, Bing Z Carter, PhD, Yoshihide Hayashizaki, MD PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-136587

Published: 2020

Journal Articles

High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML

Muharrem Muftuoglu, MD, Po Yee Mak, Vivian Ruvolo, MS, Yuki Nishida, MDPhD, Peter P. Ruvolo, PhD, Bing Z Carter, PhD, Michael Andreeff, MD PhD

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-143371

Published: 2020

NARROW

Targeting Co-Regulatory Feedback Loop of MYC and GSPT1 By MYC/GSPT1 Dual Degradation Is Synthetic Lethal in Combination with Ven/Aza in TP53 Mutant Acute Myeloid Leukemia Stem and Progenitor Cells

Reactivation of p53 in TP53 -Y220C Mutant AML: Mechanism of Action and Mechanism-Based Drug Combinations

Stem-Cell Enriched Cellular Hierarchy of TP53 Mutant Acute Myeloid Leukemia Is Vulnerable to Targeted Protein Degradation of c-MYC

Novel Hypomethylating Agent Ntx-301 Exhibits Anti-Leukemia Activity in Venetoclax-Resistant and TP53-Mutant AML

Calibrated Release IL15 Bivalent CD33 and/or FLT3 and NOT Emcn Logic Gated Gene Circuit CAR-NK Cell Therapy (SENTI-202) in Venetoclax Resistant Patient Derived Xenograft Acute Myeloid Leukemia Models

Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2

Mitophagy As a Novel Cell-Protective Mechanism Against Mitochondrial Ferroptosis in Acute Myeloid Leukemia

Epichaperome inhibition targets TP53- mutant AML and AML stem/progenitor cells

Inhibition of Menin, BCL-2, and FLT3 Combined with a Hypomethylating Agent Cures NPM1/FLT3 -ITD/-TKD Mutant AML in a PDX Model

Mitochondrial Regulation of Ferroptosis in Acute Myeloid Leukemia

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

C-MYC Targeting By Degradation: Novel Dual c-Myc/GSPT1 Degrader GT19715 Induces TP53 -Independent Cell Death in Acute Myeloid Leukemia and Lymphomas

Enhanced p53 Activation By Dual Inhibition of MDM2 and XPO1 Disrupts MYC Transcriptional Program and Restores Sensitivity to BCL-2 Inhibition in Ven/HMA Resistant AML

Combined Inhibition of Bcl-2 and Mcl-1 Circumvents Resistance of TP53 Deficient/Mutant AML to BH3 Mimetics

Co-Targeting E-Selectin/CXCR4 with GMI-1359 Facilitates AML Stem Cell Mobilization and Protects BM Niches from Anti-Leukemia Therapy

Co-Targeting Intrinsic and Extrinsic Apoptosis to Maximize Cell Death Induction in Venetoclax-Resistant AML Cells

Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML

Targeting Mcl-1 Enhances the Activity of Tyrosine Kinase Inhibitor Gilteritinib in FLT3 Mutated AML

BCL2A1 : A Novel Target in Refractory Acute Myeloid Leukemia with FLT3 -ITD/D835 Dual Mutations

High Dimensional Interrogation of Stress Response Patterns and Cell Death Modes in AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only